Skip to content
lifestyle.the-newshub.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Oculis Holding AG
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis
October 22, 2026
Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
October 20, 2026
Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease
October 19, 2026
Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day
October 7, 2026
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
October 1, 2026
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
August 24, 2026
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company
August 10, 2026
Oculis Reports Q2 2026 Financial Results and Provides Company Update
August 6, 2026
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
August 3, 2026
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
July 2, 2026
1
2
Next Page
→